South Korean dermal biotech firm Skinmed has received MFDS approval to begin Phase 1 clinical trials for SMD-101 (ariptotide), a peptide-based local muscle relaxant designed as an alternative to botulinum toxin. The trial, enrolling 54 healthy adults at Chungnam National University Hospital, will evaluate pharmacokinetics, safety, and muscle-relaxation efficacy. For overseas aesthetic buyers and distributors, this signals a potential new injectable category that could reshape the neurotoxin market.
Drug mechanism and differentiation
SMD-101 is a peptide drug candidate that directly binds to acetylcholine receptors at nerve terminals, unlike conventional botulinum toxin products that must penetrate cells. This mechanism may offer faster onset, reversible effects, and reduced risk of immunogenicity—key advantages for clinics seeking safer, more predictable aesthetic treatments.
Clinical trial design and endpoints
The Phase 1 study will assess pharmacokinetic properties, safety, and tolerability in 54 healthy volunteers. Researchers will use CMAP (compound muscle action potential) as a pharmacodynamic marker to confirm local muscle relaxation. Skinmed previously validated safety and recovery potential in non-clinical studies.
Regulatory and channel signals
MFDS IND approval marks official recognition of Skinmed’s peptide drug development capabilities. If Phase 1 data prove favorable, SMD-101 could enter a market dominated by botulinum toxin type A products (e.g., Botox, Dysport, Xeomin). Overseas distributors should monitor this candidate as a potential high-margin, differentiated injectable for aesthetic and therapeutic indications.
What buyers should watch
Importers and clinic buyers should track SMD-101’s Phase 1 results, particularly safety and muscle-relaxation duration compared to existing neurotoxins. Skinmed’s peptide platform may also enable combination products with dermal fillers or skincare actives. Early engagement with the company could secure first-mover access in key markets.
Sourcing context
Skinmed is a South Korean dermal life-science company specializing in peptide-based therapeutics. The company’s pipeline includes additional peptide candidates for aesthetic and dermatological indications. South Korea’s MFDS is a stringent regulator, and IND approval there often signals readiness for global clinical development.
Source: Read the original report | Published: June 09, 2026